- Home
- MLYS vs ORIC Comparison
MLYS vs ORIC Comparison
Compare MLYS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLYS | ORIC |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 783.0M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLYS | ORIC |
|---|---|---|
| Price | $32.90 | $8.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $47.33 | $19.73 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 02-11-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.24 | $3.90 |
| 52 Week High | $47.65 | $14.93 |
Technical Indicators
Market Signals| Indicator | MLYS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 27.95 | 39.06 |
| Support Level | $34.21 | $7.84 |
| Resistance Level | $37.70 | $8.92 |
| Average True Range (ATR) | 1.55 | 0.38 |
| MACD | -0.17 | 0.14 |
| Stochastic Oscillator | 2.72 | 65.90 |
Price Performance
Historical ComparisonAbout MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.